Caseware UK (AP4) 2023.0.135 2023.0.135 2023-12-312023-12-31falsetrue2023-01-01No description of principal activity1413true 08462829 2023-01-01 2023-12-31 08462829 2023-12-31 08462829 2022-01-01 2022-12-31 08462829 2022-12-31 08462829 c:Director1 2023-01-01 2023-12-31 08462829 c:Director3 2023-01-01 2023-12-31 08462829 c:Director5 2023-01-01 2023-12-31 08462829 c:RegisteredOffice 2023-01-01 2023-12-31 08462829 d:PlantMachinery 2023-01-01 2023-12-31 08462829 d:PlantMachinery 2023-12-31 08462829 d:PlantMachinery 2022-12-31 08462829 d:PlantMachinery d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 08462829 d:OfficeEquipment 2023-01-01 2023-12-31 08462829 d:OfficeEquipment 2023-12-31 08462829 d:OfficeEquipment 2022-12-31 08462829 d:OfficeEquipment d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 08462829 d:ComputerEquipment 2023-01-01 2023-12-31 08462829 d:ComputerEquipment 2023-12-31 08462829 d:ComputerEquipment 2022-12-31 08462829 d:ComputerEquipment d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 08462829 d:OwnedOrFreeholdAssets 2023-01-01 2023-12-31 08462829 d:CurrentFinancialInstruments 2023-12-31 08462829 d:CurrentFinancialInstruments 2022-12-31 08462829 d:CurrentFinancialInstruments d:WithinOneYear 2023-12-31 08462829 d:CurrentFinancialInstruments d:WithinOneYear 2022-12-31 08462829 d:ShareCapital 2023-12-31 08462829 d:ShareCapital 2022-12-31 08462829 d:RetainedEarningsAccumulatedLosses 2023-12-31 08462829 d:RetainedEarningsAccumulatedLosses 2022-12-31 08462829 c:FRS102 2023-01-01 2023-12-31 08462829 c:Audited 2023-01-01 2023-12-31 08462829 c:FullAccounts 2023-01-01 2023-12-31 08462829 c:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 08462829 d:WithinOneYear 2023-12-31 08462829 d:WithinOneYear 2022-12-31 08462829 c:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 iso4217:GBP xbrli:pure
Company registration number: 08462829







FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31 DECEMBER 2023


INTEGRA BIOSCIENCES LIMITED






































img06f9.png                        

 


INTEGRA BIOSCIENCES LIMITED
 


 
COMPANY INFORMATION


Directors
T Schrofer 
R Fougere 
R Rhodes 




Registered number
08462829



Registered office
Magna House
18-32 London Road

Staines-Upon-Thames

Surrey

TW18 4BP




Independent auditors
Menzies LLP
Chartered Accountants & Statutory Auditor

Magna House

18-32 London Road

Staines-Upon-Thames

TW18 4BP





 


INTEGRA BIOSCIENCES LIMITED
 



CONTENTS



Page
Statement of Financial Position
1
Notes to the Financial Statements
2 - 6


 


INTEGRA BIOSCIENCES LIMITED
REGISTERED NUMBER:08462829



STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2023

2023
2022
Note
£
£

Fixed assets
  

Tangible assets
 4 
52,042
15,785

  
52,042
15,785

Current assets
  

Stocks
  
1,088,114
918,797

Debtors: amounts falling due within one year
 5 
842,766
1,088,582

Cash at bank and in hand
  
1,260,742
1,996,506

  
3,191,622
4,003,885

Creditors: amounts falling due within one year
 6 
(1,328,009)
(1,080,849)

Net current assets
  
 
 
1,863,613
 
 
2,923,036

Total assets less current liabilities
  
1,915,655
2,938,821

  

Net assets
  
1,915,655
2,938,821


Capital and reserves
  

Called up share capital 
  
10,000
10,000

Profit and loss account
  
1,905,655
2,928,821

  
1,915,655
2,938,821


The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
T Schrofer
Director
Date: 26 August 2024

The notes on pages 2 to 6 form part of these financial statements.

Page 1

 


INTEGRA BIOSCIENCES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1.


General information

The company is a private company limited by shares, incorporated and domiciled in England and Wales. The address of the registered office is disclosed on the company information page. The address of the principal place of business is Unit 2 Rivermead, Pipers Way, Thatcham, Berkshire, RG19 4EP.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

 
2.2

Turnover

Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reliably measured. Turnover is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before turnover is recognised:

Sale of goods

Turnover from the sale of goods is recognised when all of the following conditions are satisfied:
a valid purchase order has been received for the sale;
the invoice has been raised per the purchase order and;
the goods have been shipped.

Rendering of services

Turnover from a contract to provide services is treated as deferred income and recognised as turnover on a monthly basis over the period of the contract until the expiry of the contract.

 
2.3

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, using the straight-line method.

Depreciation is provided on the following basis:

Plant and machinery
-
15%
straight line
Leasehold improvements
-
20%
straight line
Computer equipment
-
33%
straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

Page 2

 


INTEGRA BIOSCIENCES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.4

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a weighted average basis.

At each reporting date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.5

Financial instruments

The company only enters into basic financial instrument transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in ordinary shares.

 
2.6

Foreign currency translation

Functional and presentation currency

The company's functional and presentational currency is GBP.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.

 
2.7

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates income.

 
2.8

Pensions

Defined contribution pension plan

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payment obligations.

The contributions are recognised as an expense in profit or loss when they fall due. Amounts not paid are shown in accruals as a liability in the Statement of Financial Position. The assets of the plan are held separately from the company in independently administered funds.

Page 3

 


INTEGRA BIOSCIENCES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

2.Accounting policies (continued)

 
2.9

Dividends

Equity dividends are recognised when they become legally payable. Interim equity dividends are recognised when paid. Final equity dividends are recognised when approved by the shareholders at an annual general meeting.


3.


Employees

The average monthly number of employees, including directors, during the year was 14 (2022 - 13).


4.


Tangible fixed assets





Plant and machinery
Leasehold improvements
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 January 2023
27,129
73,031
-
100,160


Additions
38,841
-
7,800
46,641



At 31 December 2023

65,970
73,031
7,800
146,801



Depreciation


At 1 January 2023
11,344
73,031
-
84,375


Charge for the year on owned assets
8,001
-
2,383
10,384



At 31 December 2023

19,345
73,031
2,383
94,759



Net book value



At 31 December 2023
46,625
-
5,417
52,042



At 31 December 2022
15,785
-
-
15,785

Page 4

 


INTEGRA BIOSCIENCES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

5.


Debtors

2023
2022
£
£


Trade debtors
794,863
1,017,840

Amounts owed by group undertakings
228
-

Other debtors
25,503
18,085

Prepayments and accrued income
22,172
52,657

842,766
1,088,582



6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Trade creditors
16,713
36,067

Amounts owed to group undertakings
781,397
576,332

Corporation tax
42,824
-

Other taxation and social security
71,663
40,706

Other creditors
6,498
2,334

Accruals and deferred income
408,914
425,410

1,328,009
1,080,849



7.


Commitments under operating leases

At 31 December 2023 the company had future minimum lease payments due under non-cancellable operating leases for each of the following periods:

2023
2022
£
£


Not later than 1 year
27,673
26,867

27,673
26,867


8.


Parent Company

Integra Biosciences Holding AG, a company incorporated in Switzerland, is the parent company of the smallest group for which consolidated financial statements are drawn up of which the company is a member. The parent company's registered office is Tardisstrasse 201, 7205 Zizers, Switzerland.

Page 5

 


INTEGRA BIOSCIENCES LIMITED
 


 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

9.


Auditors' information

The auditors' report on the financial statements for the year ended 31 December 2023 was unmodified.

The audit report was signed on 27 August 2024 by Andrew Cook FCA (Senior Statutory Auditor) on behalf of Menzies LLP.

 
Page 6